PRESS RELEASE published on 05/28/2024 at 19:00, 2 years 3 months ago JTC Team to Host the Virtual Investor Pitch Conference on June 17-18, 2024 JTC Team announces Virtual Investor Pitch Conference on June 17-18, 2024, featuring live video webcast presentations with Q&A. Participating company line-up to be revealed later Investor Relations JTC Team Virtual Investor Pitch Conference Live Video Webcast Q&A
BRIEF published on 05/23/2024 at 16:35, 2 years 4 months ago GRI Bio (NASDAQ : GRI) participe à Virtual Investor CEO Connect Relations Avec Les Investisseurs Communications D'entreprise Biographie Du GRI Investisseur Virtuel Connexion Du PDG
BRIEF published on 05/23/2024 at 16:35, 2 years 4 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect Investor Relations Corporate Communications GRI Bio Virtual Investor CEO Connect
PRESS RELEASE published on 05/23/2024 at 16:30, 2 years 4 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect JTC Team announces CEO Connect segment with GRI Bio's Marc Hertz, PhD, covering recent achievements and upcoming milestones. Virtual Investor platform offers more videos GRI Bio Virtual Investor CEO Connect JTC Team Communication Strategies
BRIEF published on 04/25/2024 at 15:50, 2 years 5 months ago Moleculin Biotech souligne le rôle de l'annamycine dans le traitement de la LMA dans le segment des investisseurs virtuels du JTC Essais Cliniques Opportunité D'investissement Biotechnologie Moléculaire Annamycine Traitement LMA
BRIEF published on 04/25/2024 at 15:50, 2 years 5 months ago Moleculin Biotech Emphasizes Annamycin's Role in AML Treatment in JTC Virtual Investor Segment Clinical Trials Investment Opportunity Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 04/25/2024 at 15:45, 2 years 5 months ago Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team Moleculin CEO highlights Annamycin's differentiation in AML treatment landscape and investment opportunity. Positive interim data shared in 'What This Means' segment Investment Opportunity Clinical Trial Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 10/18/2023 at 16:00, 2 years 11 months ago JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023
Published on 09/26/2026 at 01:00, 9 hours 59 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 9 hours 59 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 12 hours 44 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 17 hours 29 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 19 hours 59 minutes ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 07:45, 3 hours 14 minutes ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 10 hours 58 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 16 hours 29 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 18:00, 16 hours 59 minutes ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26
Published on 09/25/2026 at 17:45, 17 hours 14 minutes ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 17 hours 19 minutes ago Availability of the 2026 half-year financial report
